Hepatocellular carcinoma in Central Europe: prognostic features and survival.

PubWeight™: 1.45‹?› | Rank: Top 5%

🔗 View Article (PMC 1728163)

Published in Gut on January 01, 2001

Authors

M Schöniger-Hekele1, C Müller, M Kutilek, C Oesterreicher, P Ferenci, A Gangl

Author Affiliations

1: Universitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie, University of Vienna, Austria.

Associated clinical trials:

TACE Combined With Iodine-125 Seeds Implantation for HCC | NCT03322280

Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus (STUHCCPVTT) | NCT04069949

Articles citing this

Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int (2008) 2.10

The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol (2002) 2.03

Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut (2005) 1.91

Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut (2005) 1.54

Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One (2012) 1.25

Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol (2008) 1.01

Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol (2015) 0.98

Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One (2014) 0.97

Positron emission tomography/computed tomography with (18)F-fluorodeoxyglucose identifies tumor growth or thrombosis in the portal vein with hepatocellular carcinoma. World J Gastroenterol (2007) 0.96

Clinicopathological features and outcomes of young patients with hepatocellular carcinoma after hepatectomy. World J Surg (2011) 0.93

Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open (2016) 0.91

Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol (2014) 0.89

Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World J Hepatol (2015) 0.89

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer (2001) 0.88

Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany. Int J Clin Exp Med (2010) 0.86

Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. PLoS One (2016) 0.85

New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol (2015) 0.84

Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems. PLoS One (2014) 0.83

Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol (2016) 0.82

Hepatocellular carcinoma--rising incidence, changing therapeutic strategies. Wien Med Wochenschr (2006) 0.82

Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. World J Gastroenterol (2016) 0.81

Construction of a regulable gene therapy vector targeting for hepatocellular carcinoma. World J Gastroenterol (2003) 0.81

Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection. Oncotarget (2016) 0.81

Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival. Virchows Arch (2005) 0.78

Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis. Dig Dis Sci (2015) 0.77

Challenges of advanced hepatocellular carcinoma. World J Gastroenterol (2016) 0.77

Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol (2016) 0.77

Phenotype and function of CXCR5+CD45RA-CD4+ T cells were altered in HBV-related hepatocellular carcinoma and elevated serum CXCL13 predicted better prognosis. Oncotarget (2015) 0.76

Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding. Oncotarget (2016) 0.75

Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study. J Exp Clin Cancer Res (2009) 0.75

Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment. Medicine (Baltimore) (2017) 0.75

Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study. World J Gastroenterol (2017) 0.75

A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Saudi J Gastroenterol (2016) 0.75

Hepatitis B and C viruses and survival from hepatocellular carcinoma in the Arkhangelsk region: a Russian registry-based study. Int J Circumpolar Health (2013) 0.75

Efficacy of External Beam Radiation-Based Treatment plus Locoregional Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis. Biomed Res Int (2016) 0.75

Efficacy of three-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. Onco Targets Ther (2016) 0.75

Stratified Platelet-to-lymphocyte Ratio: A Novel Target for Prognostic Prediction of Hepatocellular Carcinoma after Curative Liver Resection. J Clin Transl Hepatol (2017) 0.75

New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol (2017) 0.75

Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience. Onco Targets Ther (2017) 0.75

A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus. J Clin Transl Hepatol (2017) 0.75

Percutaneous ethanol instillation therapy for hepatocellular carcinoma - a randomized controlled trial. Wien Klin Wochenschr (2008) 0.75

Articles cited by this

Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 17.03

Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer (1954) 12.77

Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67

Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med (1991) 5.69

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg (1991) 3.12

Compensated cirrhosis: natural history and prognostic factors. Hepatology (1987) 3.01

Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology (1994) 2.99

NIH conference. Hepatocellular carcinoma. Ann Intern Med (1988) 2.94

Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg (1992) 2.76

A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol (1999) 2.38

Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer (1996) 2.26

Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology (1991) 2.25

Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci (1991) 2.12

Multivariate survival analysis using Cox's regression model. Hepatology (1988) 2.00

Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med (1998) 1.93

Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst (1997) 1.86

Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer (1989) 1.85

Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology (1990) 1.52

Treatment of hepatocellular carcinoma. Hepatology (1997) 1.39

Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol (1998) 1.33

Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology (1993) 1.26

Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology (1992) 1.24

p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res (1997) 1.23

Prognostic factors for survival in hepatocellular carcinoma. Cancer Res (1988) 1.16

Prognosis of unresectable hepatocellular carcinoma: an evaluation based on multivariate analysis of 90 cases. Hepatology (1991) 1.15

Treatment of small hepatocellular carcinomas. Lancet (1992) 1.13

Occurrence of Australia antigen in chronic hepatitis in Italy. Gastroenterology (1972) 1.09

Characteristics of hepatocellular carcinoma in Italy. J Hepatol (1998) 1.08

Clinical features and prognosis of hepatocellular carcinoma in Britain in relation to age. Age Ageing (1994) 1.00

Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer (1993) 0.97

Treatment of hepatocellular carcinoma. Digestion (1998) 0.94

Treatment of hepatocellular carcinoma in patients with cirrhosis. J Hepatol (1997) 0.94

[Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic]. Z Gastroenterol (1997) 0.84

Articles by these authors

Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev (2000) 4.06

Localization and capacity of proton pumps in roots of intact sunflower plants. Plant Physiol (1984) 3.60

Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther (2013) 3.59

Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology (1997) 3.52

Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A (1998) 3.46

Photosynthetic O2 formation tracked by time-resolved x-ray experiments. Science (2005) 3.35

Gender differences in long-term survival of patients with colorectal cancer. Br J Surg (2001) 3.18

Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood (2000) 2.70

Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut (2006) 2.53

Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med (2000) 2.43

Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet (2001) 2.40

Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat (2003) 2.33

The NF-M transcription factor is related to C/EBP beta and plays a role in signal transduction, differentiation and leukemogenesis of avian myelomonocytic cells. EMBO J (1993) 2.33

Influence of sex, age, body mass index, and smoking on alcohol intake and mortality. BMJ (1994) 2.31

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21

Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol (1998) 2.17

Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med (1989) 2.15

Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol (1996) 2.14

Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. Aliment Pharmacol Ther (2013) 2.12

ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr (2006) 2.11

Diamond stents for palliation of malignant bile duct obstruction: a prospective multicenter evaluation. Endoscopy (2001) 2.07

13C-urea versus 14C-urea breath test: is there still a need for 14C-urea? Nucl Med Commun (1998) 2.06

Crystal structure of MalK, the ATPase subunit of the trehalose/maltose ABC transporter of the archaeon Thermococcus litoralis. EMBO J (2000) 2.05

Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther (2013) 2.04

Postcremation diagnosis from an electric shaver. Lancet (2001) 2.02

Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer (2003) 1.99

Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology (2001) 1.92

Evaluation of a virtual endoscopy simulator for training in gastrointestinal endoscopy. Endoscopy (2002) 1.91

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther (2011) 1.85

Intensive care unit stay is prolonged in chronic alcoholic men following tumor resection of the upper digestive tract. Acta Anaesthesiol Scand (1996) 1.85

Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol (1990) 1.80

Cloning and heterologous expression of a cDNA encoding 1-deoxy-D-xylulose-5-phosphate reductoisomerase of Arabidopsis thaliana. FEBS Lett (1999) 1.79

[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol (2010) 1.76

Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut (2003) 1.76

Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin) Thromb Haemost (1997) 1.73

Detection of the His1069Gln mutation in Wilson disease by rapid polymerase chain reaction. Ann Intern Med (1997) 1.64

Hepatitis B virus clearance by transplantation of bone marrow from hepatitis B immunised donor. Lancet (1997) 1.63

Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology (1998) 1.62

Energy metabolism in acute and chronic renal failure. Am J Clin Nutr (1990) 1.60

Noninvasive quantification of brain edema and the space-occupying effect in rat stroke models using magnetic resonance imaging. Stroke (2004) 1.59

Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer (1996) 1.56

Confocal imaging of glutathione redox potential in living plant cells. J Microsc (2008) 1.54

Conflicting results of ileoscopy and small bowel double-contrast barium examination in patients with Crohn's disease. Endoscopy (1998) 1.53

Autocrine growth induced by kinase type oncogenes in myeloid cells requires AP-1 and NF-M, a myeloid specific, C/EBP-like factor. EMBO J (1992) 1.53

Inflammatory mediators in bronchoalveolar lavage fluid and plasma in leukocytopenic patients with septic shock-induced acute respiratory distress syndrome. Crit Care Med (1998) 1.50

Wilson disease in two consecutive generations: an exceptional family. Am J Gastroenterol (2001) 1.50

Molecularly cloned simian immunodeficiency virus SIVagm3 is highly divergent from other SIVagm isolates and is biologically active in vitro and in vivo. J Virol (1989) 1.49

Molecular epidemiology of Encephalitozoon cuniculi and first detection of Enterocytozoon bieneusi in faecal samples of pigs. J Eukaryot Microbiol (1996) 1.49

Renal function after cardiopulmonary bypass surgery in cyanotic congenital heart disease. Int J Cardiol (2000) 1.47

IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-kappa B is decisively involved in the expression of IL-9. J Immunol (2001) 1.46

Long-term results after video-assisted thoracoscopic surgery for first-time and recurrent spontaneous pneumothorax. Ann Thorac Surg (2000) 1.45

Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest (2007) 1.45

Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology (1997) 1.44

Engagement of the T-cell receptor during positive selection in the thymus down-regulates RAG-1 expression. Proc Natl Acad Sci U S A (1992) 1.43

Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ. J Invest Dermatol (1991) 1.43

Functions of cyclin A1 in the cell cycle and its interactions with transcription factor E2F-1 and the Rb family of proteins. Mol Cell Biol (1999) 1.43

Incorporation of 1-deoxy-D-xylulose into isoprene and phytol by higher plants and algae. FEBS Lett (1997) 1.42

Loss and degradation of enzyme-bound heme induced by cellular nitric oxide synthesis. J Biol Chem (1995) 1.41

Beneficial effect of pharmacological modulation of the GABAA-benzodiazepine receptor on hepatic encephalopathy in the rat: comparison with uremic encephalopathy. Hepatology (1991) 1.41

[Hepatitis B and C: incidence and regional distribution of hospitalizations in Austria]. Wien Klin Wochenschr (2000) 1.40

Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut (2002) 1.40

ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr (1997) 1.40

Beta-carbolines in chronic alcoholics following trauma. Addict Biol (1996) 1.40

Large-scale clustering of cDNA-fingerprinting data. Genome Res (1999) 1.40

Plasma atrial natriuretic factor in cirrhotic patients with ascites. Effect of peritoneovenous shunt implantation. Gastroenterology (1988) 1.39

[Psychiatrists who took shelter in French-speaking Switzerland from 1933-1945]. Rev Med Suisse Romande (1992) 1.39

Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood (2000) 1.38

Severe pulmonary hypertension reversed by antibiotics in a patient with Whipple's disease. Thorax (1997) 1.38

Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1 beta and TNF alpha. Kidney Int (1993) 1.37

Forceps biopsy and brush cytology during endoscopic retrograde cholangiopancreatography for the diagnosis of biliary stenoses. Scand J Gastroenterol (1997) 1.37

Isolation of atypical mycobacteria from tap water in hospitals and homes: is this a possible source of disseminated MAC infection in AIDS patients? J Infect (1995) 1.36

Localization and organization of phenol degradation genes of Pseudomonas putida strain H. Mol Gen Genet (1995) 1.33

High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis. J Hepatol (2001) 1.33

The transposable elements resident on the plasmids of Pseudomonas putida strain H, Tn5501 and Tn5502, are cryptic transposons of the Tn3 family. Mol Gen Genet (1998) 1.33

Structural and oxidation state changes of the photosystem II manganese complex in four transitions of the water oxidation cycle (S0 --> S1, S1 --> S2, S2 --> S3, and S3,4 --> S0) characterized by X-ray absorption spectroscopy at 20 K and room temperature. Biochemistry (2005) 1.33

Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med (1999) 1.32

HLA antigens in inflammatory bowel disease. Gastroenterology (1982) 1.31

Initial experience with technetium-99m HM-PAO brain SPECT. J Nucl Med (1987) 1.30

Distribution of the mevalonate and glyceraldehyde phosphate/pyruvate pathways for isoprenoid biosynthesis in unicellular algae and the cyanobacterium Synechocystis PCC 6714. Biochem J (1998) 1.29

Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur J Immunol (1998) 1.27

Differential inhibition of HLA-D- or SB-directed secondary lymphoproliferative responses with monoclonal antibodies detecting human Ia-like determinants. J Immunol (1982) 1.27

Focally enhanced gastritis: a frequent type of gastritis in patients with Crohn's disease. Gastroenterology (1997) 1.27

Has total bowel rest a beneficial effect in the treatment of Crohn's disease? Clin Nutr (1983) 1.25

Analysis by sequential immunoprecipitations of the specificities of the monoclonal antibodies TU22,34,35,36,37,39,43,58 and YD1/63.HLK directed against human HLA class II antigens. Immunobiology (1986) 1.24

Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother (2009) 1.24

Alternatively activated macrophages actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro. Immunology (1997) 1.24

Regulation of RAG-1 and CD69 expression in the thymus during positive and negative selection. Eur J Immunol (1994) 1.23

Cell-mediated cytotoxicity in hepatitis A virus infection. Hepatology (1987) 1.23

The spectrum of pathology in central core disease. Neuromuscul Disord (2002) 1.23

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol (2005) 1.22

Two Encephalitozoon cuniculi strains of human origin are infectious to rabbits. Parasitology (1997) 1.21

Molecular cloning and characterization of the mouse CD163 homologue, a highly glucocorticoid-inducible member of the scavenger receptor cysteine-rich family. Immunogenetics (2001) 1.19

Neuronal-glial interactions and behaviour. Neurosci Biobehav Rev (2000) 1.18